Has the NIB share price now peaked at $8?

Can the NIB train keep chugging higher or is it time to disembark?

| More on:
a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price has been a very strong performer over the last six months.

Since this time in November, the private health insurer's shares have raced 19% higher.

As a comparison, over the same period, the benchmark ASX 200 index has gained just 1.5%.

This leaves the NIB share price trading at $8.00, which is just 20 cents short of its 52-week high.

Why has the NIB share price outperformed?

Investors have been buying NIB's shares due to its improved outlook and recent update.

That update revealed that the company has raised its guidance for net policyholder growth for Australian residents in FY 2023 to 4% to 5% from 3% to 4%.

Management also revealed that ancillary claims are returning to normal, hospital claims are showing a modest uplift but remain subdued, and its net margins remain strong with a gradual return to its 6% to 7% target expected over the longer term.

Can its shares keep rising or have they peaked?

As things stand, the broker community appears to believe that the NIB share price may have peaked for the time being.

For example, Citi and Morgans both have the equivalent of buy ratings on its shares but with price targets of $7.85 and $7.55, respectively. These are both lower than where the company's shares trade today.

Elsewhere, Macquarie and Morgan Stanley have the equivalent of hold ratings with price targets of $7.65 and $6.95, respectively, and Ord Minnett has a lighten rating with a $7.00 price target.

Though, that doesn't necessarily mean that the NIB share price can't keep rising. It just means that brokers are unlikely to be recommending its shares to clients until they are trading at a more attractive level.

In addition, a strong result in August from NIB could have brokers revisiting their models and price targets. Fingers crossed for shareholders that this happens.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Healthcare Shares

Guess which ASX small cap stock is jumping on 'significant milestone'

This stock is ending the week in style. Let's see what is giving its shares a boost today.

Read more »

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »